Core Viewpoint - SELLAS Life Sciences Group Inc. has experienced significant stock price appreciation, with over 200% increase in the last six months and approximately 45% year-to-date growth, indicating strong investor interest and potential for a short squeeze due to high short interest of 27.21% [1] ASH 2025 Data Presentation - In December 2025, SELLAS Life Sciences presented clinical data from its Phase 2 study of SLS009 combined with azacitidine and venetoclax for patients with relapsed or refractory acute myeloid leukemia, showing a 46% overall response rate and 29% achieving complete response [2] - The median overall survival for this patient population was significantly higher than the expected 2.6 months, reaching 8.9 months in the least pretreated cohort [3] Phase 3 REGAL Trial Update - An update on the Phase 3 REGAL trial was provided in December 2025, evaluating Galinpepimut-S as a maintenance therapy for AML patients after second complete remission, with the trial continuing without modification as per the Independent Data Monitoring Committee's recommendation [4] - As of December 26, 2025, the trial reported a pooled number of 72 events, approaching the 80 events required for final analysis [5] Technical Analysis - SELLAS Life Sciences is trading at $5.50, close to its 52-week high of $5.51, reflecting a 364.40% increase over the past year, with strong bullish momentum indicated by trading above key moving averages [6] - The stock is 31.6% above the 20-day simple moving average and 137.4% above the 200-day simple moving average, with a recent golden cross further supporting a bullish outlook [6] - Current technical indicators show an RSI of 72.66, suggesting potential overbought conditions, while the MACD indicates continued bullish momentum [7] Benzinga Edge Rankings - The Benzinga Edge scorecard for SELLAS Life Sciences highlights a bullish momentum score of 99.01, indicating the stock is significantly outperforming the broader market [8] - The stock's strong performance may attract more investors seeking growth opportunities in the biopharmaceutical sector [9]

Core Points - SELLAS Life Sciences hosted an R&D Day to discuss advancements and future directions in their research and development efforts [1][2] - The agenda included opening remarks by the CEO, followed by discussions on the AML treatment landscape and the company's product offerings [2][3] Group 1: Company Overview - The company is focused on addressing unmet needs in the treatment of Acute Myeloid Leukemia (AML) [2] - GPS and SLS009 are positioned within the current standards of care for AML [2] Group 2: Research and Development - Dr. Omer Jamy provided context on the AML treatment landscape, highlighting areas of unmet need [2] - Dr. Panagiotis Tsirigotis and Dr. Dragan Cicic discussed the mechanism of action and differentiation of GPS, along with details of the Phase III REGAL trial [3]

Group 1 - Sellas Life Sciences Group Inc. announced the immediate exercise of warrants for 22.4 million shares, raising $31 million in gross proceeds [1][2] - The new warrants, priced at $2 per share, will be exercisable immediately and will expire five years from issuance [2] - The company is preparing for a virtual R&D Day on October 29, 2025, to discuss treatments for acute myeloid leukemia, including its lead product candidate GPS and SLS009, a CDK9 inhibitor [3][4] Group 2 - Sellas Life Sciences focuses on developing novel cancer therapies, with its lead candidate being galinpepimut-S (GPS), targeting the WT1 protein for various cancers [4] - SLS009 is being developed as a CDK9 inhibitor for certain types of leukemia, with preliminary results suggesting its potential role in treating T-cell prolymphocytic leukemia [3][4]